Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy.
about
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary glandMutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasStat3 mediates expression of autotaxin in breast cancerLAP2 is widely overexpressed in diverse digestive tract cancers and regulates motility of cancer cells.Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes.Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells.Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformationRECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch.Interleukin-6 and pro inflammatory status in the breast tumor microenvironmentAntitumorigenic potential of STAT3 alternative splicing modulationStat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and TransformationMouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signalingRole of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspectsTCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis.Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancySTAT3 as a target for inducing apoptosis in solid and hematological tumorsTriple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects.Potential role of naturally derived polyphenols and their nanotechnology delivery in cancer.The role of intratumoral and systemic IL-6 in breast cancer.gp130: a promising drug target for cancer therapy.STAT3 activation in infection and infection-associated cancer.Syndecan-1 modulates β-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation.EGFR inhibitor BIBU induces apoptosis and defective autophagy in glioma cells.Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth.Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages.Tyrphostin ErbB2 Inhibitors AG825 and AG879 Have Non-specific Suppressive Effects on gp130/ STAT3 Signaling.Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling.The Role of TCPTP in Cancer
P2860
Q24669531-50CC737D-CB56-4163-A670-6B6457E4999BQ24669579-2622D15B-EA60-4C0B-9878-B90472788E66Q34091068-BD49DF1B-569B-4ABE-A7C5-69DA31923392Q34321439-D340464A-B9CB-42DC-B7CC-76DF1BBE2731Q34440657-5C7CBEDE-4D67-43A1-A1CD-A694A63E76BDQ34698039-1B3F6248-1D9B-4837-8DF9-123F7042F97DQ34989115-17DEB1D9-869B-4E0D-9FC1-789255347E4DQ35130808-3456A5C2-5070-479F-BA54-4A3730D4CC1FQ35427020-5D76C1A6-278A-4764-AF27-87E4BB5163B8Q35471200-273AF079-461D-4C7C-9240-F1349E7ECF9BQ35906313-C3DC3C96-05A3-4ABB-9F51-B9BED9D4F41AQ36130808-B3B1E8ED-B206-46F5-87D8-C4DE7AA3717CQ36458771-80C8818B-398F-4CC7-83DC-4CEE68A590DAQ36497007-381CD95C-1644-4429-830F-5E31629A9994Q36560020-C1F572C5-226A-44A2-A0BF-589B4A91C92EQ36713529-190A2F93-01D1-48E5-8E3A-5245976BB47EQ36737884-6EFDD917-7FCD-4779-8D9E-0A029EF5F4BCQ37029162-E708CE12-1C75-4D23-B4A0-994EC63CF612Q37600589-7019D010-BB00-4BB0-A1AD-4ED58DEDEB84Q38027835-6FECB3C2-1B9E-4BD0-BB7B-991DB287447DQ38078272-85B8F45B-A902-4C34-BF3A-26F9E2435BBBQ38093468-48E08C63-2C05-4C12-B029-BB42EF1A67C1Q38149939-4353EC9E-3ED5-452B-8E7C-1BE4A5533DFEQ39145689-521CD892-17D8-4A70-AD41-7ABDCA13A89EQ39216398-92F3E00E-E0DA-4A99-998A-0DC40661F39BQ39321309-0B4E6323-326A-42AF-8F6D-0B489CB26993Q39691985-2F458184-2261-453D-ABE5-A54E26CD3084Q39715544-FEA35C2E-F9F6-4FD8-9368-76DF8F6930CEQ42698939-DC0F10E3-ACCA-4CC5-8AEE-A0936FB8DB7BQ55308550-121EAD57-4FCB-4BC7-93F8-6077E29A7C05Q58377593-FFC1C08F-C37E-4FC8-A12B-E53CA08A63B6
P2860
Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Inhibition of gp130 signaling ...... d inhibits in vivo malignancy.
@en
type
label
Inhibition of gp130 signaling ...... d inhibits in vivo malignancy.
@en
prefLabel
Inhibition of gp130 signaling ...... d inhibits in vivo malignancy.
@en
P2093
P1433
P1476
Inhibition of gp130 signaling ...... d inhibits in vivo malignancy.
@en
P2093
Heike Dahmen
Katri S Selander
Kevin W Harris
Latania Watson
Melinda Merrell
Peter C Heinrich
P304
P356
10.1158/0008-5472.CAN-03-2516
P407
P577
2004-10-01T00:00:00Z